T2EVOLVE

Accelerating Development and Improving Access to CAR and TCR-engineered T cell therapy in Europe

[T2EVOLVE @t2evolve_imi]

A regular question we face is why are patients at higher risk of infections after CAR T-cell therapy?
Four leading hematology experts explain the medical background for this risk, and a patient shares their powerful personal experience after receiving CAR T-cells.

Looking to learn more or share our resources? The video is available with subtitles in 6 languages.
Watch it here: https://t.co/LgFXSAoEu7

[T2EVOLVE @t2evolve_imi]

And stay tuned, we will soon release a concept paper with concrete recommendations for advancing platform-based development models in Europe.

#ATMP #RegulatoryScience #CellTherapy #GeneTherapy #PlatformTechnologies #T2EVOLVE #JOIN4ATMP #ESGCT #EMA #Innovation #Extrapolation

[T2EVOLVE @t2evolve_imi]

What if we could reduce duplication, optimize design, and fast-track next-generation therapies using what we already know?

That’s exactly what we explored at the ESGCT Annual Meeting 2024 in Rome, where #T2EVOLVE and @JOIN4ATMP co-hosted a high-level roundtable with regulators, industry, and academia.

Key Takeaways from the report:
✅ Platform approaches and data extrapolation can support faster, safer development
✅ EU regulators welcome prior knowledge—when scientifically justified
✅ Early engagement and robust comparability studies are crucial for success
✅ Lessons from COVID-19 mRNA platforms show the power of data reuse

Case studies from VHIO, Fondazione Telethon, and Friends of Cancer Research highlighted strategies for building regulatory trust while accelerating innovation.

Read the report: https://t.co/8TTg2ReSUa

[T2EVOLVE @t2evolve_imi]

How can we make Informed Consent Forms more understandable?

At #EBMT2025 in Florence, T2EVOLVE hosted a round table on reducing unnecessary complexity of Informed Consent Forms (ICFs) for patients in clinical trials.
We are proud to share highlights on the T2EVOLVE website including:

📝 Our report of the discussion
🎬 A short video with highlights from the discussion

Discover the report and video on our website: https://t.co/ZKx0y5VuKv

#T2EVOLVE #InformedConsent #PatientEngagement #CART #ClinicalTrials

[T2EVOLVE @t2evolve_imi]

A sincere thank you to the T2EVOLVE Work Group for Patients and Caregivers (WGPC)!
T2EVOLVE is committed to providing patient-centered information on the innovative CAR T-cell treatment. 
The Work Group for Patients and Caregivers (WGPC) plays a crucial role in defining content that addresses real needs of both patients and their caregivers.
We would like to express a sincere thank you to all the members of the WGPC for their valuable insights and contributions during our meeting on March 25. 
Your feedback is essential as we continue to refine and improve the resources we provide.
Together, we can make a meaningful impact!
🔗 https://t.co/RKN8rBiSik
#T2EVOLVE #CARTtherapy #PatientEducation

[T2EVOLVE @t2evolve_imi]

Looking for patient-friendly information about CAR T-cell treatment?
The T2EVOLVE Patient Hub offers valuable information about this ground-breaking treatment, available in six different languages.
Gain insights through our explainer videos for patients and caregivers.
🔗 https://t.co/RKN8rBiSik
#CARTcelltherapy #PatientInformation #T2EVOLVE

[T2EVOLVE @t2evolve_imi]

🧬 #T2EVOLVE Round Table on ICF at #EBMT25: Reimagining Informed Consent in CAR T-cell Therapy 📝
Still buzzing from the powerful panel discussion hosted by #T2EVOLVE at #EBMT25 on the future of Informed Consent Forms  in advanced therapies! 💬💡
Clinicians, regulators, industry experts, ethicists, and patient advocates all came together with one shared goal: empowering CAR T patients through better consent—not overwhelming them.
✅ Clarity is care
✅ Consent is more than just a signature
✅ Clear communication should be the standard, not the exception
A huge thank you to our incredible panelists and engaged audience for driving this essential conversation forward.
🚀 Stay tuned for the position paper and next steps from #T2EVOLVE and the Coalition for Reducing Bureaucracy in Clinical Trials!
#T2EVOLVE #ICF #InformedConsent #PatientEngagement #CARTtherapy #AdvancedTherapies

[T2EVOLVE @t2evolve_imi]

T2EVOLVE is looking forward to the upcoming roundtable session at #EBMT25 on April 1 from 9:00 to 10:30 on implementing Patient-Friendly Informed Consent Forms in CAR-T Clinical Studies: Insights and Solutions.

Representatives from patients, study sponsors, study investigators, the German ethics committee, and the Coalition for Reducing Bureaucracy in Clinical Trials (RBinCT), will discuss key findings from recent surveys, ethical and regulatory challenges, and actionable solutions to make ICFs more effective tools for enabling patients to make truly informed and free decisions about clinical trial participation.

#T2EVOLVE #ClinicalTrials #CARTtherapy #PatientCentricity #InformedConsent #RBinCT

[T2EVOLVE @t2evolve_imi]

We are thrilled to share exciting updates on preclinical advancements driven by the #T2EVOLVE consortium. With a focus on innovation and collaboration, our efforts continue to bridge the gap between ground-breaking research and clinical applications in #cellulartherapy.
View our key highlights: https://t.co/M0LOmcuRX7

#CART #preclinicalmodels

[VJHemOnc @VJHemOnc]

What is pentanoate, and how may it be used to guide patient outcome prediction and #CARTCell engineering?

Maik Luu of @Uniklinikum_Wue speaks on this in an interesting interview from #CART25:

🎥 https://t.co/tMiwKxvPe1

#ImmunoOnc #HemOnc @TheEBMT @EHA_Hematology

[T2EVOLVE @t2evolve_imi]

We would like to thank the #T2EVOLVE community for joining us for our yearly meeting at the #EHA-EBMT Meeting (#CART25) in Strasbourg, France. From achieving new milestones to holding a fruitful joint workshop with the GoCART Coalition on leveraging synergies across consortia, we look forward to the rest of 2025. Learn about T2EVOLVE: https://t.co/ghEFN7AKSO

[T2EVOLVE @t2evolve_imi]

We congratulate #T2EVOLVE Project Managers Elise Pennings and Maik Luu on each receiving a 5th Emerging Investigators #EHA-EBMT Joint Fellowship Awards in the Field of Cell Therapy and Immunotherapy at #CART25 on patient reported outcomes of CAR T-cell therapy and microbiome-derived metabolites as a guide to patient outcome prediction.

[T2EVOLVE @t2evolve_imi]

#T2EVOLVE aims to accelerate access to CAR T-cell Therapy across Europe. Through heartfelt patient stories, expert interviews, and resources, we offer patients an open access, central place to learn about what they can expect from this innovative treatment and how to navigate its complexities.

The Patient Hub is available in 6 languages: English, French, German, Dutch, Spanish, and Italian.

Learn more now: https://t.co/RKN8rBiSik

[T2EVOLVE @t2evolve_imi]

T2EVOLVE is proud to announce our presence at the 51st Annual Meeting of @TheEBMT in Florence, Italy. Consortium representative Carmen Sanges from the @Uniklinikum_Wue will chair and moderate a discussion on Patient-Friendly Informed Consent Forms in CAR-T Clinical Studies on April 1 from 9:00 to 10:30.

Learn more about the session: https://t.co/G3EghuHtuF

#EBMT25 #CARTtherapy

[T2EVOLVE @t2evolve_imi]

How can we accelerate development and access to immunotherapy with TCR and CAR immune cells? From the importance of #CARTtherapy to #T2EVOLVE's aims, you can now learn more about our breakthrough alliance in our new explainer video.
Watch now: https://t.co/0JpwXt2LrU

[T2EVOLVE @t2evolve_imi]

#T2EVOLVE will take part in the EHA-EBMT Eutopean CAR T-cell Meeting #CART25 in STrasbourg, France. Join us for our roundtable discussion on February 7 at 17:30 as we discuss immune-related adverse outcome pathways and preclinical models.
Register now: https://t.co/2azvR2GPau

[T2EVOLVE @t2evolve_imi]

Connect with #T2EVOLVE at the 11th @ITOCconference in Munich where Project Coordinator Michael Hudecek will be giving an update on RORing cancer with novel CAR T cell on April 5 at 10:00.
View the meeting: https://t.co/SrFm3C4kXj
Abstract submission for the meeting is also open.

[European Hematology Association @EHA_Hematology]

Do you have new research on #CARTcells that you would like to share with the world? Late-breaking abstract submission for the #EHA-@TheEBMT European CAR T-cell Meeting (#CART25) is now open until January 12.
Share your research with the world of CAR T-cell therapy in Strasbourg, France: https://t.co/FORQnrk3xH

@young_eha @AnnaSureda5 @MariaThemeli1

[T2EVOLVE @t2evolve_imi]

2024 has been a big year for #T2EVOLVE. From presentations at international meetings to offering more resources on #CARTcells to patients, we have continued working towards increased development and access to this innovative treatment. Learn more about our successes below 👇

[T2EVOLVE @t2evolve_imi]

@EHAPatient @knowyournodes @EHA_Hematology @IMFmyeloma @EuroGct @AcuteLeuk @Kersten_MJ @JulioDelgadoHem @MyelomaEurope

[T2EVOLVE @t2evolve_imi]

What determines eligibility for #CARTcell therapy? In this informative video, a patient shares their personal story, & 3 experts explain key criteria & reasons why some patients might not qualify. Now available in 6 languages: https://t.co/O03CFYDFcd

 #PatientStory #Hematology